A Randomized, Double-blind, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs GSK 2798745 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Aug 2017 Status changed from active, no longer recruiting to completed.
- 15 Aug 2017 Planned End Date changed from 11 Aug 2017 to 21 Aug 2017.
- 15 Aug 2017 Planned primary completion date changed from 11 Aug 2017 to 21 Aug 2017.